| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 16.12 | 58.2% |
| Total Income | 16.12 | 58.2% |
| Expenditure | 25.39 | 59.6% |
| PBT | — | |
| Net Profit | -8.70 | 51.8% |
| OPM | -57.56% | 1.43pp |
| NPM | -53.96% | 2.27pp |
| EPS | -0.32 | 78.2% |
Carlsmed Reports Q1 2026 Revenue of $16.1 Million, Up 58% Y-o-Y
06 May 2026 · 6 May, 1:42 am
Summary
Carlsmed, Inc. reported financial results for the first quarter ended March 31, 2026. Revenue for the quarter was $16.1 million, a 58% increase compared to the first quarter of 2025. Gross profit increased to $12.4 million, with a gross margin of 77.1%. The company has raised its full year 2026 revenue guidance to $72 million to $77 million.
Key Highlights
- 1
Carlsmed's first quarter 2026 revenue was $16.1 million, representing a 58% increase year-over-year.
- 2
Gross profit for the first quarter of 2026 was $12.4 million, compared to $7.6 million for the first quarter of 2025.
- 3
Gross margin increased to 77.1% for the first quarter of 2026, compared to 74.9% for the first quarter of 2025.
- 4
The company's full year 2026 revenue guidance was raised to $72 million to $77 million.
- 5
A study published in Global Spine Journal demonstrated a 74% reduction in reoperations with aprevo® personalized lumbar implants.
- 6
The first procedure using the corra™ personalized cervical plating system was performed in February.
Management Comments
Mike Cordonnier
We began 2026 with strong momentum, delivering 58% year-over-year revenue growth, publishing meaningful clinical data, and debuting new products to continue to advance our mission of improved patient outcomes and reduced cost of healthcare. The publication of peer-reviewed data from a retrospective cohort study in Global Spine Journal demonstrates a 74% reduction in revision rates for aprevo®, which represents one of the most significant advancements in reducing reoperations in adult spinal deformity over the past two decades. With our first full commercial quarter for aprevo® Cervical and the launch of our corra™ patient-specific fixation portfolio later this year, we believe we are well positioned for continued growth and innovation throughout 2026.”
Informational and educational content only. Not investment advice.